Condition: Systemic Lupus Erythematosus (SLE) · Sponsor: Hangzhou Qihan Biotech Co., Ltd.
This study is a single-arm, open-label clinical study designed to evaluate the safety and tolerability of QT-019B in subjects with refractory SLE and to determine the RD. The study has two phases: dose escalation and dose expansion, with a planned enrollment of 18-24 subjects.
This description comes directly from the study's public registry record.
Zhijiang Wang · +86 151 5712 6379 · zhijiang.wang@qihanbio.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Ustc Anhui Provincial Hospital | Hefei, Anhui, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07444307